STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX), signed an agreement with Sony DADC Austria AG (”Sony DADC”), based in Anif/Salzburg, Austria, to acquire all of the shares of its BioSciences business, Sony DADC BioSciences GmbH (”Sony DADC BioSciences”), which is a wholly-owned subsidiary of Sony DADC. The acquisition is expected to be completed by the end of the third quarter 2016.

In the current financial year, ending on March 31, 2017, the company is expected to generate sales of around € 17 million with slightly positive earnings contributing to STRATECs EBIT. Based on current planning, the management teams expect a continuously growing EBIT margin to reach the current group’s EBIT margin by 2020. The company valuation set in the sale and purchase agreement amounts over € 30 million.

Building on Sony DADC’s experience in high-precision optical disc manufacturing, Sony DADC induced 6 years ago the formation of its BioSciences business. Sony DADC BioSciences is a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications. The company has a unique combination of skills and technologies including nano- and microstructuring, coating technologies, polymer sciences, and automated assembly. Its customers include global players in highly regulated markets as well as innovative start-ups. The company currently has around 120 employees.